Patient Safety

Showing 101 - 115 of 115
Filters
Note you may be able to select more filters from the select box on the right.
Innovation 'Elevator Pitch':
UK developed patient focused Population Health solution pulls cross sector data (i.e. GP, Acute, Mental health, etc) and performs analytics and intelligent cohort finding that can identify patients with reported unexplained symptoms.  
Overview of Innovation:
ArtemusICS supports a health system to analyse population data and identify specific gaps, health inequalities and unwarranted variations in its population’s health. ArtemusiCS secure web accessed hosted system provides a wide range of tools, dashboards, selection and filtration options to identify and create patient cohorts. ArtemusICS can then further identify costs, utilisation and gaps in care.

Collecting data from Acute, GP, Community, Mental, Social and Ambulance, ArtemusICS provides commissioners and providers with a tool to identify cohorts of patients, and understand the integrated care needs of a population right down to an individual. It contains analytical tools to allow for LTC risk, EOL risk, Frailty, Social isolation, etc to be collated and presented in one picture. It also allows for evaluation of interventions (i.e outcomes) and identification of RoI.

It has a unique attributes based architecture, where all data items are linked to one or more “attributes”, based on their coding (i.e. Snomed, Read, ICD10, etc). Inherently future proof and expandable, it allows us to utilise Machine Learning and AI techniques to drill through large data sets to find correlations and trends in specified data types, such as the symptoms presented in the MUS cohorts.

ArtemusICS operates on three distinct levels:
  • Overview Dashboards: provide whole-population analytics with facilities to filter down to key patient cohorts. A range of Dashboards provides commissioners and clinicians pertinent population count, event counts, service and usage counts and costs; with the facility to then drill through to cohort and patient specific views.
  • Cohort Manager enables the user to review sub-lists of patients, caseload management groups or individual patients against a range of detailed views including conditions, events, measures, timelines and management lists. Venn diagrams offering cohort comparisons to enable care planners and clinicians to pin-point a specific cohort with a specific set of attributes for intervention and care management.
  • Patient view provides a range of views specific to patient conditions, medications, diagnosis, events and measures, supporting the clinical user to improve diagnosis and plan care.
In addition, our remote monitoring technology can also collect surveys such as PHQ,GAD7, HADs etc
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
ArtemusICS currently identifies all patients with a mental health condition, including those with unexplained medical symptoms; this achieved by the use of Read, SNOMED and ICD10 codes.   Through the development of artificial intelligence and the use of inferential statistics, we would be able to provide rich case finding and provide greater insight in the nature of the specific problem associated with the patients.
Repeat admissions, vague multiple comorbidities and results of screening are all available in the ArtemusICS database and could inform the AI development. Using the ArtemusICS impactability management module, commissioners will be able to assess adherence to care pathways and also monitor the impact of the given interventions.
As patients with medically unexplained symptoms are often seen in multiple care and social settings, ArtemusICS would create and provide a clear picture of all the cross sector activities associated with the patients in order to develop bespoke interventions.
This affords both primary (and potentially) secondary care clinicians the opportunity to introduce patients to a specific MUS care pathway that will deal with the specific requirements of MUS in a timely manner that will prevent the condition becoming chronic.  Effective stratification of patients could aid in a reduction in need for acute secondary care outpatients, reducing unnecessary healthcare costs and freeing up resources.
Online Discussion Rating
6.00 (2 ratings)
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
As for the health system above
Current and planned activity: 
Docobo are continuously adding additional functionality to its solutions, usually to meet the requests from our NHS customers or our own staff
The uniqueness of ArtemusICS is that Docobo fully owns and controls all of the product. It is not a 3rd party product that we sell, like many others, so we can easily add functionality and are not at the mercy of the overseas priorities of a 3rd party product
What is the intellectual property status of your innovation?:
Fully owned by Docobo
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
3
Read more
Hide details
Adrian 23/05/2018 - 19:42 Sign Posted Login or Register to post comments
Innovation 'Elevator Pitch':
QxMD is a company dedicated to creating point-of-care applications created by for healthcare professionals, with a global community of 1.9 million clinicians, medical students, scientists and researchers and are free to download and use at any time. 
Overview of Innovation:
Healthcare professionals need to stay up to date on the latest medical research and topic reviews to provide optimal care. Unfortunately, the process of content discovery is broken with research artificially compartmentalised by publishers and hidden behind countless institutional paywalls.

At QxMD, we believe that knowledge translation– the process by which new knowledge is incorporated into clinical practice – is an important and unsolved challenge for our health care system. Read uses smart algorithms to ensure that each and every user has a dedicated newsfeed of research that applies to their practice. 
With Read, Institutional Edition, organisations can seamlessly integrate their existing journal subscriptions and existing proxy service to provide a platform for their clinical staff to access content which matters to their individual practices. It is built with features designed to improve patient care and reduce costs. 

The Promoted Research feature is used by institutions who want to disseminate research that impacts areas of care the most within their organisation. For example, a Hospital with high rates of Sepsis can use this tool to promote guidelines that reduce Sepsis cases with higher guarantees their clinical staff will discover the research and apply it to the next patient. 

Librarians and Knowledge Managers can take advantage of smart analytics to understand which journal subscriptions are performing the best and worst and also which journals are most popular, which they don't subscribe to.

NHS Trusts are already adopting QxMD, with over 100,000 users in the UK alone. 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
  • Better educatad and up-to-date staff, specific to their practice
  • Cost saving on journal subscription costs
  • Improved patient care
  • Challenges identified and tackled via the Promoted Research feature
  • Easy to discover and access research from any smart device
  • Links with OpenAthens for instant access to subscribed content. 
Initial Review Rating
2.60 (1 ratings)
Benefit to WM population:
  • Better educated healthcare professionals who can identify the latest research and apply it to patient care
  • Less chances of mis/under diagnosis, readmission or even death
  • Improved quality of care
Current and planned activity: 
  • Existing NHS Trust clients, including the largest Mental Health Trust in the UK
  • Continue to grow our userbase, which is already at 100,000 UK users, with the support of Trusts and other stakeholders. 
What is the intellectual property status of your innovation?:
  • We have designed and developed the platform entirely in-house. No white-labelling. A completely unique tool built by Healthcare Professionals for Healthcare Professionals. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Jimmy Connoley 19/06/2018 - 12:56 Publish 2 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Clinical decision making improved via proactive digital remote monitoring. Together driving cost efficiencies, improving patient outcomes & avoiding hospital admissions. (CE Class 1a: data server sits within HSNC:  proven ¯ 67% admissions: scalable)
Overview of Innovation:
CliniTouch Vie is a digital health solution that reduces unnecessary hospital admissions.
 
CliniTouch Vie is a locked-down tablet with integrated 3G for intensive monitoring, education & empowerment with integrated direct messaging & video support.  Dynamic care plans & evidence-based algorithms enable automatic triage for healthcare teams.  Fast & simple to implement for the most at-risk patients. 
 
Launched in 2016, system is CE marked & MHRA approved. An evidence based digital health platform that clinically supports patients to better manage their condition. It has the flexibility to be adapted for data analytics & clinical decision-making support in chronic disease management (eg COPD, heart failure & diabetes), frailty & assisted discharge programmes for ambulant & non-ambulant patients
 
Clinical & economic evidence has been generated from trials with 300 respiratory patients [Ghosh et al, 2016, https://doi.org/10.12968/bjhc.2016.22.3.123]. Our evidence based digital solution increases patient access to care & promotes greater clinician-patient collaboration for the 15million people with LTCs. It drives timely, proactive intervention, minimising need for more acute costly care enabling sustainable long-term outcomes success
 
USPs:
Evidence based: Study published in the British Journal of HC Management showed 67% reduction in unscheduled COPD admissions & saving of £2,278 per patient pa. (NB: programme continues to deliver same level of savings)
 
Patient-centred: Personalisation of goals, metrics & parameters makes system truly patient centred providing real-time remote monitoring closer to home to improve patient experience & outcomes whilst generating savings
 
Secure & integrated: Data server sits within HSNC enabling it to push-pull data securely between healthcare provider & service users. Includes bespoke integrated secure video-conferencing platform with end-to-end encryption, allowing remote monitoring of medical conditions, improving quality of life & avoiding unnecessary admissions
 
Flexible Modular Architecture: Enables clinically validated question sets re: symptoms, to be easily tailored to specific therapy areas for qualitative data collection
 
Tiered Service: no upfront costs to NHS on PAYG basis:
- Digital platform integrated into existing healthcare pathways
- Light touch triage service informing local health teams of urgent priority patients for interventions
- Fully-Managed digital platform and nurse-led service providing triage & interventions
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
CliniTouch Vie has proven benefits and can be scaled up easily across the wider regions:
  • improved patient outcomes:
  • 67% reduction in COPD emergency admissions;
  • 13% improvement in CAT score
  • 97% of patients using CliniTouch Vie will further reduce distress and discomfort from conditions exacerbations
These were supported by:
  • improved access to healthcare: 24/7 access to healthcare, average 110 interventions per patient per annum (500% increase)
  • targeted and personalised health interventions: 7,250 personalised clinical interventions (data from 66 patients over 12 months)
  • data analytics: real-time clinical dashboards for clinical teams to prioritise patient needs; prioritised only 38% of patient clinical recordings required intervention within a 24-hour period
 

 
Patients are educated and supported to interpret the data to gain an improved understanding of their health status.CliniTouch Vie:
  1. Educates patients: supporting people to make health life choices through improving the understanding of their disease and self-management skills
  2. Enhances care for patients with chronic conditions: informing and engaging patients as part of NHS prevention agenda and creating a patient-provider collaboration
  3. Provides data analytics: making more targeted and personalised health interventions, by using disease specific algorithms to differentiate when one patient’s history or recent environmental exposures indicates a higher likelihood of flare up than another
  4. Improves patient safety: providing real time clinical and well-being data to identify early warning signs of health deterioration, medication adherence and self-management education
  5. Reduces hospital activity: providing real time management of high risk patients to prevent admissions
  6. Supports early discharge: providing hospital level diagnostics and monitoring in the home, enabling early discharge and can be used for remote clinical support post-surgery or in care-home settings
  7. Delivers workload efficiencies: supporting better patient self-management, reducing need for direct interventions and enabling staff to focus on priority patient care
  8. Offers locality wide cost savings: reduced demand leads to reduced NHS activity
 
Initial Review Rating
5.00 (2 ratings)
Benefit to WM population:
The West Midlands priorities that CliniTouch Vie can address are:
  • P2: Long Term Conditions: whole system, person centred approach
  • P4: Wellness, healthy aging and prevention of illness
  • P8: Digital Health
 
Our vision is for CliniTouch Vie to contribute towards and support the West Midlands wider vision to develop a worldwide reputation for delivering healthcare through digital technologies, proven to deliver sustainable improved outcomes and create wealth.  We have already demonstrated that it can deliver on all fronts with high risk COPD patients and is being adopted for Heart Failure, Diabetes, Cancer and Frailty pathways.  With an ageing population, often with co-morbidities, it can be used to support a more patient-centric approach to health care services in the region.
 
CliniTouch Vie supports health and wealth benefits as is a flexible, real-time remote monitoring solution, facilitating earlier discharge, prevent readmissions, reduce risk of future exacerbations and improve self-management through our inbuilt education resources.  CliniTouch Vie delivers a proactive approach to tackling symptoms, preventing exacerbations and slowing health deterioration, resulting in reduced NHS costs.  The system has an extensive data collection of medical, lifestyle, biometric and daily activity.
 
Targeting patients who are at risk or have multiple hospital admissions could significantly reduce the NHS costs to the region as well as freeing up clinic and nurse time to manage a wider caseload more efficiently. With a more collaborative, integrated, patient centred approach, utilising proven remote digital health, the West Midlands could see a potential reduction in admissions by 60%+.
 
CliniTouch Vie is a locked-down tablet, with integrated 3G for intensive monitoring, education and empowerment with integrated direct messaging and video support.  Our dynamic care plans and evidence-based algorithms enable automatic triage for healthcare teams. 
 
The tablet comes in an easy to carry case with the peripherals and can be handed to the patient at home, in clinic or upon discharge and is linked directly to the clinician web-based management portal.  Data within CliniTouch Vie tablet is stored securely within the cloud and hosted on the N3.  This makes CliniTouch Vie easy to scale due to its low technology and estates requirement, whilst delivering a high quality clinical service.
Current and planned activity: 
Current:
Spirit Digital is part of Spirit Health Group and can provide one of the most comprehensive range of solutions to support patients of all ages, IT capabilities & levels of disease severity across a wide range of conditions e.g. respiratory, cardiovascular, diabetes, cancer, frailty.
 
Spirit is establishing research collaborations with academic institutions around evidence generation for AI and machine learning. This includes collaboration on a bid to the European Space Agency to further develop the technology using satellite data.

Planned:
Spirit Digital seeks WMAHSN support ta assist with introductions and marketing of CliniTouch Vie to local CCGs. 
 
Our planned NHS engagement activity programme for the next 12 months will be through a variety of channels:
  • Direct engagement with CCGs and community Trusts
  • Application to Digital Accelerator programme
  • Case study development & sharing
  • Presentations at national conferences
  • Creating user (clinicians & patients) video footage to share with CCGs
What is the intellectual property status of your innovation?:
We hold the IP for the technology and digital health algorithms.  We collaborate with Midlands based businesses, healthcare providers and universities and retain all IP for products and services.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Read more
Hide details
Emma-Jane Roberts 21/06/2018 - 12:25 Publish Login or Register to post comments
5
1
Votes
-99999
Innovation 'Elevator Pitch':
Medopad's remote monitoring platform provides clinicians with insight into patient progress in between clinic appointments. This can prevent unncessary outpatient appointments or bring forward appointments for patients who are not progressing well. 
Overview of Innovation:
The Medopad app is a health ecosystem with a patient view and a clinician view. It is very intuitive and user-friendly, having been designed with Apple in their Cupertino, California labs. 

Patient app
Patients interact with Medopad through a single smartphone app or via connected devices and sensors. Instead of multiple apps for each disease, patients have a single, centralised point of access via the Medopad platform. The Medopad app is composed of different modules and divided into four user-friendly and intuitive sections: patient profile, data collection, patient dashboard, and learning & education. Medopad provides 100+ data collection modules ranging in functionality: medication and symptom trackers, photo and video capture, tele-consultation, and questionnaires. We also provide activity-based modules for specific disease indications including the 6-minute walk test, used by cardiovascular patient cohorts to avoid travel into clinic. We can also integrate devices and sensors, i.e. glucometers and spirometry. To enable self-management, we can provide in-app videos and digital leaflets for patient education. Equally important, patients have access to their dashboard, providing a visually engaging view of trends in their own health and wellbeing data.

Clinician dashboard
The Medopad platform is built specifically for each clinician and their patient cohort via a custom integration. Clinicians monitor and manage their patient cohort through a web-based dashboard, where they can view trends in patient data that otherwise were not available to them before. Empowered with increased information, stakeholders can create customised alerts to identify patients who are progressing poorly. By extension, data availability allows clinicians to provide a high level of personalisation in between clinic appointments by sending patients customised notifications to support self-management.

 
 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Medopad's solution enables clinicians to spot health deterioration sooner, preventing costly complications.  To name a few, we are working the Royal Free NHS Teaching Hospital, Guy's and St. Thomas's, Royal Salford, and Chelsea and Westminster.

At Guys' and St. Thomas' hospital, we are working with both community nurses and hospital vascular consultants to monitor venuous leg ulcer healing. While there are no estimates for the total cost burden of venous leg ulcers specifically, the total cost of acute and chronic wounds to the UK NHS is estimated to range from £4.5 to £5.1 billion, with 78% of costs falling on community NHS services for chronic wounds (Guest et al 2015). This pilot is currently underway. Patient's leg ulcers are photographed by themselves or the community nurse during wound dressing changes. Patients' acitivity is also tracked, as increasing mobility is a sign of a healing leg ulcer. This pilot is being used by vascular consultants to identify deteriorating wounds earlier, which may necessitate a move from a community-based management to hospital-based interventions. 

At the Royal Salford, we are working with consultants to monitor patients with renal disease. In this pilot, patients are completing tasks at home that would normally be done by the nurse. Specifically, patients are monitoring weight, blood pressure, and completing a urine test at home using Healthy IO's urine dip stick test. This saves the nures time when the patient does travel into clinic, where the nurse needs only complete the remaing blood test. Apart from saving nurses time during clinic, renal consultants are able to monitor patient progress in between appointments. If patients' blood pressure and weight are not deteriorating, the consultant may postpone the appointment, and equally, if indicators seem to be worsening, the consultant can provide timely care by bringing the patient in sooner. Renal disease is a costly condition; the NHS in England spent an estimated £1.45 billion on CKD in 2009–10. By monitoring patient progress, there is potential to reduce some of these costs by reducing disease progression and complications. 
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The Medopad platform provides clinicians with insight into patient progress in between clinic appointments, this has the potential to provide patients with preventative and timely care by spotting problems sooner (as described in the previous section). For the patient, prevention of further deterioration means improved quality of life. Additionally, the platform has the potential to reduce unnecessary clinic appointments for patients.

At the Royal Free, patients with peripheral arterial hypertension (PAH - a rare disease) are using the Medopad smartphone to avoid travelling into clinic for appointments. Instead, patients complete a six-minute walk test (a measure of disease progression) at home. Since it can be done from home, patients can do this more frequently, on a weekly basis, which provides clinicians with richer data on which to assess patient progress. Due to the nature of the condition, PAH patients suffer from symptoms like breathlessness that are made worse with activity. By avoiding long distance travelling to one of seven specialist PAH centres, patients' health is improved and they have a better experience of care. 

At the Harley Street Clinic, we have worked with children that have a rare form of brain cancer (DIPG). Parents recorded videos of their child performing certain tasks and recorded additional health data. The clinician was able to more frequently monitor the children's progress without putting additional undue strain on both parent and child. Using the platform in this way was particularly improtant for vulnerable patients, such as these children, not to mention reducing the burden on parents.  
Current and planned activity: 
As mentioned in the previous sections, our solution and deployments have been co-developed with clinical experts and innovators across several top UK NHS teaching hospitals. 

We are currently looking for partners in the West Midlands, such as the AHSN, clinicians, and nurses, to engage in several pilot projects across a range of disease areas. Medopad is offering pilot projects free of charge for 12 months as a way to gather evidence of effectiveness and cost-effectiveness for our solution. As a part of the project, we include implementation and ongoing support.

In the longer term, we are looking to provide a transformative experience of care by providing intelligent and AI-powered clinical support systems to move the needle from reactive to preventative care. In that vein, we are looking for motivated and committed health care professionals to work with us in this journey. 
What is the intellectual property status of your innovation?:
Medopad's IP is related to its smartphone app and clinician web-portal. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Marija Trachtenberg 02/07/2018 - 19:34 Sign Posted Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Giving one drop of blood for analysis by SOMAscan informs me of my current health status, and helps my doc give me the right advice to reverse or prevent further disease development, or guide their treatment recommendations that will work first time!
Overview of Innovation:
The measurement of 5,000 blood proteins (a quarter of the human protein repertoire) is now possible on a reproducible and industrial scale in clinically-accredited central lab settings. Prior analysis of hundreds of thousands of study subjects' and patient blood samples, whose basic & physiological measurements, life style and clinical histories have been collated, has been used to create a suite of health status defining algorithms that define risk of disease event occuring over 1-5 year time horizons, rates of development, and likelihood of response to alternative intervention that are available.  Whereas rudimentary 'disease risk' insights such as Framingham cardiovascular diasease (CVD) risk scores and QRISK2 are used in public health, primary care and specialist acute care settings to augment disease prevention or guide optimal treatment choices, it is now possible to expand this range of probablistic medicine insights.  Expanding the repertoire beyond CVD to include pre-diabetes conversion to full diabetes or development of complications (amputations, kidney failure, blindness) that lead to costly or catastrophic outcomes, is a starting point.  However, diseases such as non-alcoholic fatty liver disease and steatohepatitis, which leads to liver cancer & failure is another silent killer whose development can be revealed just by applying a different status-prognosis algorithm to protein measurements derived from the same blood sample.  Chronic disease management and care accounts for ~70% of healthcare costs with diabetes alone consuming 10% of the NHS' entire budget and so these are worthy of attention for  prevention, early disease interception (at a reversible stage), or optimising existing care paths that maximise available resources to deliver disease management interventions.  Our primary focus is to prolong and improve population wellbeing such that patient treatment outcomes leads to broad adoption.  However, whereas traditional diagnoses rely heavily on clinical symptoms, SomaLogic's AI-derived algorithms consider the molecular underpinnings of disease.  Clinically-defined diseases are treated in standardised ways which doesn't always work.  Identifying patients with treatment-refractory disease could help target those into research programmes including clinical trials for novel regimens or pharmacological agents.  A secondary output of routine adoption could be creation of an accelerated trial recruitment resource to attract pharma partners.
Stage of Development:
Evaluation stage - Representative model or prototype system developed and can be effectively evaluated
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Advanced diagnostics, genomics and precision medicine / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Healthcheck, although ultimately funded by Public Health England, commissioned by City Councils and delivered through contracted CCGs/GPs, is of questionable value.  A battery of tests whose results are combined with additional clinical parameters and a consultation with a GP or practice nurse, is designed to pre-empt intervention in patients with rising risk for cardiovascular disease or identified as having 'frank' disease.  The net contribution based on opportunity savings delivered to the NHS and the cost of delivering the HealthCheck programme is close to zero.  The repertoire of diseases whose status can be tested for, could be expanded to include multiple silent diseases, as well as provision of range of physiological status-related insights that could complement the patient review process.  For example, patients at risk of developing frank diabetes could be managed more objectively and successfully.  A reduction by 1% of patients converting to full diabetes could equate to £100 million/year by their avoidance of costly complications such as stroke, amputations, kidney failure and blindness.  Avoidance of liver failure associated with liver fibrosis, could contribute further significant opportunity savings: Coupling life style (e.g. dietary education or excercise on prescription) or emerging pharmacological interventions with conveniently measured disease status insights will be required.  However, rather than creating increased burden on NHS resources, provision of clinically validated insights but could also create opportunities for third party organisations beyond the NHS in offering relevant health-maintaining or disease-reversing solutions.
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
In a county in which 29% of the population is clinically obese there is a higher risk compared to the majority of the UK population, for diabetes and also fatty liver disease-related complications.  Treatment costs for the latter alone costs the NHS (England) around £1billion/year.  Providing disease risk insights to citizens and their health practictioners, particuarly if the information is objective and made actionable, could be used to support increased health literacy, increase patient activation (motivation), and support the best choice and resource-optimal delivery of advice and clinical interventions.  Ultimately, compliance with such advice and insights will improve the healh of the local population, reduce the burden of dependancy on long-term chronic disease care, and perhaps even result in development of a health-focused preventive health solution provider market.
Current and planned activity: 
SomaLogic has submitted plans for implementation of diabetes risk and complication development predicting algorithms in the routine primary care setting in Leeds (one CCG and 3 GPs). The objective is to use the more objective patient profiling (identified through hypertention clinics) to promote deeper patient enagement measured through increased patient uptake of commissioned nutritional education programmes and/or gym by prescription.  Logistics around blood collection, processing, analysis and data delivery and presentation will be evaluated and optimised, after whcih there is scope to expand this initiative to a wider geographical region.  However, there is scope to evaluate the utility of additional disease status (risk), and prognostication algorithms within the different clinical settings and associated clinical workflows, in neighbouring geographies.
What is the intellectual property status of your innovation?:
SOMAscan is a patented proprietary protein measurement technology.  Algorithms developed using artifical intelligence to mine for associations between patient characteristics, lifestyle histories, clinical interventions and decades of clinical follow-up/outcome data (2 million years) that correlate with patterns for 5,000 protein measurements (mined from 2 billion protein data points), provides a highly defensible starting position.
Return on Investment (£ Value): 
Very low
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Anthony John Bartlett 11/07/2018 - 16:11 Publish 3 comments
6
1
Votes
-99999
Innovation 'Elevator Pitch':
Aurora Innovation Logo
The teleQ communication solution enables healthcare facilities to save money, drive productivity & increase patient care & satisfaction. Dynamic, inbuilt decision software mini-triages calls & contacts to the right person/service/department 1st time.
Overview of Innovation:
Aurora teleQ (TQ) is an advanced cloud-based communication solution for health care providers that need to stay available with high inbound call volumes.
 
In a busy department or clinic phones can ring continuously causing patients and staff unnecessary stress. TQ helps to address those areas that have limited resources, ensuring efficiency is maintained by getting callers directly to the person that can address their needs first time. Whether that is connecting a patient to a doctor, a ward nurse or a specialist.  
 
One of the key advantages of TQ’s dynamic, inbuilt decision software is that it can reroute calls to the most appropriate or next on duty person (e.g. locum doctor) without requesting the user (patient/carer) dial a new number. Therefore, reducing time and stress for caller, especially if they require emergency advice for themselves or a loved one. It can equally be used by staff needing to access consultants or specialist when there is a crisis or need. This reduces stress for clinical staff using the system.
 
The statistics in TQ are presented with easily accessible diagrams and provide snapshots of a department/unit’s availability and contact patterns. Based on the statistics, the department/unit can optimise its resources, so the right number of staff handle the right number of contacts at the right time. The statistics can highlight pressure points / areas where efficiencies need to be created.
 
The system can be integrated with electronic patient record systems and other systems gathering crucial patient info (ex. APPs), to immediately bring up patient details thus saving time and ensuring calls and contacts are structured.
 
TQ integrates with analogue and digital infrastructures but takes full advantage of digital and mobile communications. The importance of varied channels of communication is growing. Therefor it is essential to have a tool that brings points of communication together as more channels of communication are added to the legacy points of contact
 
The solution is made up of several modules, all in one interface. Provides a scalable & tailored, system for your requirements; you pay for the modules you need.
 
Main Modules in Aurora teleQ
  • Call back
  • Call queue
  • Duo – call back and queue
  • Response groups
  • Interactive voice menu
  • Interactive voice menu messages / extra message
  • Video
  • Chat
  • SMS
  • Email
  • Voicemail plus
Our aim is to allow you to spend more time with patients as you remove communication roadblocks.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
The NHS is facing tough challenges, dealing with an increasing volume of patients and an ageing population that will lead to ques on calls and communication. A structured and automated way to manage the volume of contacts is needed. This both for patient, carer and internal contacts.
 
Ineffective communications leave patients and staff feeling frustrated and can create a long lasting negative perception. Communication solutions need to focus on your patient’s needs and can adapt to changes within the healthcare provider, easily and efficiently.
 
The TQ platform helps a caregiver to efficiently gather information from a variety of sources at the point of contact. With the on slew of self-monitoring and APPs collecting data from patients with long-term or multiple illness, an easy consolidator is needed. TQ has several solutions that are integrated and used on a daily basis, such as; fully automated patient triage, lung capacity monitoring etc.
 
TQ provides integration into patient facing APPs, for easy communication with patients.


Aurora teleQ (TQ) is an innovative communications solution that is designed to maximise resources, provide more efficient collaboration and decision making. Thereby providing real benefits in patient care and staff efficiencies whilst reducing operating costs and stress.
 
The statistics in Aurora TQ are shown as easily accessible diagrams that provide snapshots of the unit’s availability and communication patterns. Based on the statistics, the unit can optimise its resources, so the right number of staff is assigned to handle tasks. TQ provides several management reports that provide direct decision support. Providing clear information on patient communication efficiency, staffing and competency. The statistics allow for simulation of how the unit can best plan staffing and inbound and outbound call and communication times to meet variety of availability needs and measurements.

 
In addition to the statistics, that are integrated in to the report function, a large volume of data points can be integrated into big data decision tools. This provides an overview of point of contact in relations to the rest of the organisation, allowing for better decisions. TQ builds a model that will provide more accurate decision support over time.
 
Aurora TeleQ will help NHS to enhance patient care, reduce operational costs and increase staff productivity whilst reducing stress.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Healthcare organisations are facing increasing financial and patient care level pressures. They require improved communications to provide exceptional service and best value to patients. Patients expect to be involved in decisions and kept informed.
 
Care Giver
Your telephone and text system are the gateway to your service. Staff members shouldn’t be spending time on administrative patient work, answering inappropriate calls and redirecting them than on actual patients. Aurora TeleQ (TQ) ensures a timely patient contact whilst delegating work to the contact most suited for the work. This could even mean an electronic contact for information seekers.  those who need to make contact can get through and are able to access the right help when it is needed most. TQ provides a unified communication solution that improves patient care, lowers costs and frees up the time of healthcare professionals.
 
Patient
Patients and relations will find communications more efficient and to the point. Less time spent trying to find information or getting to the correct contact. When communication with the Care Giver the communication will be more to the point and more informed. The quality will be perceived to be better & more efficient.
 
Decision support
Proficient call and communication logging enables analyses of data & provide meaningful reports about support, usage, costs, capacity & quality of service. By having these statistics at hand, you can react in real-time or identify trends, letting you make informed decisions about future resourcing & commercial needs.
 
Consultancy
Aurora consultants have a 20 years of experience in Patient communication. The intricacies of communication dynamics are part of the Aurora delivery.
 
Benefits
The Aurora TeleQ system will provide time and cost saving. How much and how is dependent on what you want to achieve. If you are focusing on internal time saving you will find that TQ will provide a time saving of some, 1 to 15+ minutes per transaction. In addition to the time saved you will experiens a more harmonious & structured work environment that will be less stressful. Do not hesitate to see what VUmc in Netherlands has experienced https://aurorainnovation.com/en/case/vumc/
 
For other customer presentations please see https://aurorainnovation.com/en/case/

Collaboration
To assist us brining our technology to the UK we are looking for a NHS partner (more details below) we would look to them to assist and support us with validation studies and trials.
Current and planned activity: 
Aurora has 20 years of expertise in patient contact and communication. Aurora consultants work closely with health & care providers to optimize the patient flow and journey. The result is a highly satisfied patient and an effective and low stress communication strategy.
 
Aurora, requires a NHS developmental partner to collaborate with us to run a test installation/Pilot (free of charge). The aim is to customise the solution to match the needs of UK healthcare and the needs of the NHS Trust or partner/s.

The NHS organisation would gain the improvments in efficiency & cost savings along with increased satisfaction of patients and Staff. The pilot process would demonstate the benefits gained in Sweden & Spain whilst helping the company uncover what adaptation & modifications are needed to the system, protocols and API’s to match UK healthcare needs as well as our legal and regulatory requirements.

NHS Partner will have the opportunity to customise a solution for their specific requirements.
 
What is the intellectual property status of your innovation?:
All IP belongs to Aurora Innovation
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
2
Read more
Hide details
Padra Sadr 26/07/2018 - 12:55 Sign Posted 1 comment
0
0
Votes

Innovation 'Elevator Pitch':
Liva Healthcare empowers patients to manage or reverse their chronic disease through expert behaviour change coaching. Liva is an evidence-based hybrid service leveraging human empathy and technology to achieve sustainable, positive health outcomes. 
Overview of Innovation:
Liva Healthcare has over 16 years of industry expertise, with over 140,000 users through the behaviour change intervention to date.  Liva is an innovative digital health coaching platform for scalable lifestyle and disease management.  
  
Winner of 'Health IT  Firm of th e Year' at the HealthInvestor Awards 2018 and 'Healthtech Innovators of the Year - Europe' at the Global Health & Pharma Awards 2018, Liva Healthcare is used  by  public healthcare, private insurance and pharma companies including : - NHS  England, AXA PPP Healthcare and Copenhagen Municipality.  
  
Liva  Healthcare’s platform facilitates ongoing,  personalised Health Coaching through an intuitive app, building a unique, empatheticbond between Health Coach and patient.  Its focus lies  in tackling chronic diseases such as type 2 diabetes, obesity and heart disease by  driving behaviour change.   
   
Currently being used in the UK, Denmark and Sweden, the app is multilingual across several languages. It is proven to work efficiently across all socio-economic backgrounds and is capable of engaging historically hard to reach areas and demographics. The service is based upon 9 to 18 months  of  continuous  patient  engagement to form new habits for good.  Each Health Coach  can  manage up to  500 patients per year full time without the loss of patient outcomes.  
  
Implementation time from get-go is normally within weeks and the platform is available as a white-label SaaS platform, or as a turn-key solution, dependent on client specifications.  
  
Liva  Healthcare has Headquarters in Marylebone, London and Copenhagen, Denmark. 
 
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Education, training and future workforce / Clinical trials and evidence / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
By helping to both prevent and cure chronic lifestyle diseases, Liva consequently relieves the cost pressures on healthcare systems.  Unhealthy lifestyles lead to significant cost pressures on healthcare systems. For example, in the UK it is claimed that type 2 diabetes costs the National Health Service (NHS) £8.8 billion per year, which equates to almost 9% of its annual budget and causes 20,000 early deaths per year. In addition, it is estimated that obesity costs the NHS over £5 billion per year.   
 
The platform allows Health Coaches to monitor up to 500 patients siumtaneously. This enables the NHS to save costs as the digital health tool can help patients come off medication safely. It also drives efficiency by enabling more patients to be monitored.  
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
The primary benefit that Liva Healthcare provides patients with is the opportunity tp make long-term, and SUSTAINABLE lifestyle changes to diet and exercise, with the help of a personal Health Coach, that can prevent or remove their lifestyle disease (e.g. type 2 diabetes, obesity or heart disease).  
 
Liva was designed to help prevent and reverse chronic diseases caused by unhealthy modern lifestyles, such as type 2 diabetes and heart disease, both of which are often caused and affected by weight gain.  The app is based on clinical research that has shown lifestyle interventions can lead to long-term lifestyle change and help patients reduce their risk of the disease or enter remission by losing weight.  
 
For example, Liva Healthcare monitored the progress of 136 patients using its digital healthcare app to prevent and roll back type 2 diabetes over a nine-month period. Over the period, 82% of the patients (112) lost weight, losing an average of 6.3kg, demonstrating signs of a successful lifestyle intervention.  
Current and planned activity: 
In response to this crisis, the NHS chose Liva as one of five providers to tackle type 2 diabetes using digital innovations. GPs can now refer patients at risk of type 2 diabetes in North East London, Humber, Coast and Vale to use the Liva app. Patients are given a personal Health Coach and an app to help monitor and track their health goals. The app is based on strong evidence that has shown lifestyle interventions - delivered digitally - can lead to long term lifestyle change and help patients with - or at risk of developing - type 2 diabetes reduce their risk of the disease or enter remission. Liva holds a firm belief that prevention is better than cure. Though, in many instances, its platform has been proven to facilitate both. 
What is the intellectual property status of your innovation?:
We are fully aligned to NHS IG and GDPR requirements, in addition to being a member of the NHS App Library and fully accredited and highly scored with ORCHA and QISMET. 
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
Simon Pickup 01/10/2018 - 15:47 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Detection of acute, chronic and very early stage diseases in real time based on tests results and alerting all authorized parties about detected problems with of the essential patient information on mobiles, tablets and computers.
Overview of Innovation:
As it could be integrated and is constantly receiving data from current lab and EHR systems, it immediately detects problems in lab test results and informs doctors about new lab data received and issues detected for a particular patient. It gives access to historical data with some valuable statistical calculated and visualised data which helps doctors to understand acute, chronic, hidden or early stage health problems over secure web/mobile/tablet applications, so doctors can see these results for making better and correct decisions any time and in any location they are in at any moment.
 
Core applications of the solution are:
1. Speeding up doctors’ workflow in hospitals. At the moment, doctors in NHS have to go to rooms where there are computers with access to lab data. Quite often, doctors spend time waiting for each other to get access to their patient blood test data.

An essential part of the solution is the mobile/tablet application which can be installed on any mobile operation system iOS/Android. Which lead to:
  • Freeing up to 2 hours of doctors’ time daily
  • Increasing patient turnaround time on average by 25%
  • Increasing time reaction on most critical acute cases up to 99% 
2. In Doctors’ practice, there have been cases when a delay in days, hours or minutes in getting lab data in time is crucial for a patient’s life.  

Platform is constantly tracking blood data from the lab system, it analyzes it and alerts about critical changes in lab tests metrics and it immediately sends notifications to related parties to pay attention on a particular case.

At the moment, it tracks more than 25+ diseases and all other blood test parameters and (early and acute): AKI + CKD (all types), Sepsis and much more.

3. Platform provides historical analysis tools for blood results and gives some related insight information for each particular test parameter, so it is quick and easy to see the problem and identify potential problems at a very early stage and apply preventive actions to avoid problems. 

4. Platform has a recommendation system which seeks potential hidden problems in results. If those potential hidden problems are found, the platform gives an explanation and list of additional tests required to confirm potential problems.

5. For management team it provides deep business insight (visulised with over the time progression) of a difference scale: Hospital, Groups of Hospitals and National level about detected problems, about performance of laboratories, doctors and etc.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Wellness and prevention of illness / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Potential impact of the Pin.Health on NHS
 
Product results in efficient improvements:
—  Increases time reaction on most critical acute cases up to 99%, that decreases the amount of fatal cases in hospitals
—  It frees up to 25% of doctors and GP’s time daily
—  Increases patient turnaround on average by 25%
—  Saves money on unnecessary blood tests and use of hospital beds

Product results in cost improvements:
—  It saves more than £18,000.00 GBP per doctor per annum
—  Decreases amount of unnecessary admissions up to 25%
—  Increases revenue up to 20% with the same medical headcount for commercial healthcare companies
—  Decreases the amount of unnecessary sales and blood test results in labs
—  Significant healthcare budget decrease on investment in huge IT project
 
Product results in patient care improvements:
—  Increases time reaction on most critical acute cases up to 99% that decreases the amount of fatal cases in hospitals
—  Early stage disease identification with more than 95%+ accuracy rate, and it keeps growing. It prevents serious illness conditions — move focus to preventative medicine
—  Decreases amount of fatal cases at the Hospital
—  Decreases number of doctors’ errors or human factors
 
Pin.Health supports the HSCIC Strategy (NHS Digital) 2015–2020 Strategy as well as some general European Union Strategies in Healthcare.
  1. Ensuring that every citizen’s data is protected
    Platform follows HIPAA, GDPR and UK Law in relation to data access and protection. 
  2. Establishing shared architecture and standards so everyone benefits
    Platform has API based on industry-standard protocol FHIR HL7 (JSON based protocol). Any trusted (pre-authorized by NHS) 3rd party applications and systems can connect to Pin.Health over a secure connection over API and get access to data it has, and results it has produced. 
  3. Implementing services that meet national and local needs
    As platform provides access to data and results it produced over API — any external trusted applications/systems can be built on top of it to solve other problems.
  4. Making better use of health and care information
    Pin.Health solves numerous problems which helps improve workflow in hospitals, speed up process of disease identification to save patients’ lifes and to avoid critical conditions, moving the focus to preventive medicine, proceed researches based on data platform aggregates. All of it implements better use of health and care information.
Initial Review Rating
4.20 (1 ratings)
Benefit to WM population:
In some doctors’ practices, there have been cases when a delay in days, hours, or even minutes in getting lab data in time is crucial to a patient’s life. Our platform solves this such challenges.

The platform is monitoring data from 3 perspectives — first it’s trying to detect acute diseases, after it recognizes chronic conditions and early stage conditions for each newly received test.
 
At the moment, we are tracking more than 25 diseases such as Acute Kidney Injury and Chronic Kidney diseases of all types, Anaemia of all types, Liver Disease and others, as well as all test parameters, whether they are out of range or not, and if they are at a chronic stage or an early stage.
 
One example is the AKI (Acute Kidney Injury) which is one of the diseases that is tracking in our system. AKI is a sudden and recent reduction in a person’s kidney function.  Despite the high incidence, AKI in hospitalized patients is characterized by a high rate of missed diagnosis. The missed diagnosis rate is about 57% even in high-income countries. In the UK, 1 in 5 emergency admissions into the hospital are associated with AKI, with up to 100,000 deaths each year in hospitals associated with acute kidney injury. From official UK NHS statistics, up to 30% could be prevented with the right care.

All in all platform leads to NHS operational, financial improvements as well as in longer and stronger health of the West Midlands population.
Current and planned activity: 
We would be interested in running the pilot project with one of the NHS Trust or Hospital for a period of 2-4 months. Afterwards, integration will be completed. To gather statistic about platform performance and getting first feedback from clinical environment, which leads to futher platform improvements and scaling benefits which platform gives over other NHS Trusts.
What is the intellectual property status of your innovation?:
Company is IP holder of the solution.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Anonymous 05/12/2018 - 00:09 Publish 3 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Viper360 is a configurable which creates a Intergrated Care Record or  Shared Care Record.  ReStart uses an incrementatl approach to interoperability helping team achieve targets, on time and on budget.
Overview of Innovation:
The Presentation Layer offers multiple users, across a range of services, a bespoke view of all available information about a patient. It supports the requirement to write-back to the source systems based on user RBAC status. This covers all clinicians, patients, social care and healthcare users.

Based on over 12 years of integration expertise and experience, the Viper360 Presentation Layer has been built to allow multiple users (clinicians, users and patients) to view, review and write back into multiple IT systems in real-time.

How is the Presentation Layer different to a portal?
A portal, such as a patient portal, offers patient centric visibility of their data which they can consent to being viewed by many clinicians. Information is managed and shared through a single-to-many relationship.
The Viper360 Presentation Layer goes further. It is a fundamentally a tool for care professionals that can be scaled to include patient interaction. In short, it offers a broader many-to-many relationship to patient data allowing conditions for professionals to interact in real-time.
Key features the of the Presentation Layer:
  • Many-to-many view vs single-to-many
  • Creates a Virtual Patient Record within the Presentation Layer
  • Supports Multi-Disciplinary Team (MDT) collaboration
  • Pulls information in real-time from any available source system
  • Minimises clinical risk by maximising data availability
  • Highly configurable offering role-based access and bespoke user views
  • Fast to deploy
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Wellness and prevention of illness / Education, training and future workforce / Wealth creation / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:
Flexible
  • Present users with relevant data at the point of care
  • RBAC compliant
  • Choose which business or clinical needs you address initially around patient flow. Such as
    • Delayed transfer of care
    • Digital pathology
    • Inappropriate A&E Attendances
    • Duplicated Testing
    • Etc.
Scalable
  • From single organisations source systems through to a fully Integrated Digital Care Record
  • Provides the functionality to include new organisations and systems as the need arises
 
Affordable
  • No need for Rip and Replace.
  • Save money by realising the full potential of existing systems.
  • Incremental spending providing early return on investment.
  • Cash releasing benefits can fund future developments.
  • Working in a mutually rewarding partnership.
.
Initial Review Rating
3.40 (1 ratings)
Benefit to WM population:
Although we have not had a Viper360 deployment in the West Midlands Region we have in others for example South West Yorkshire Partnership NHS Foundation Trust (SWYPFT) has gone live with a new clinical portal for its mental health, community, and learning disability services that has the potential to save staff significant time each year in unnecessary administration and phone calls by improving access to clinical information.  By bringing this vital information into a single view, staff do not have to spend precious time unnecessarily trying to find information or discussing patient cases with colleagues from different service departments.
 
The deployment supports a key element of the NHS’s Long Term Plan which placed a renewed emphasis on the adoption of technology to support ‘clinician-centric digital user journeys across all health settings’.
 
The trust’s clinical portal, called PORTIA, supports the NHS’ 10-year plan by reducing clinical risks associated with disparate information on different systems, and removes the duplication of data entry into specific clinical systems.
 
PORTIA is powered by ReStart’s Viper360® Presentation Layer which plugs the interoperability gap between Trust Integration Engines (TIEs) and enterprise-wide integration solutions such as electronic patient records, building towards a full shared care record.
 
Nichola Hartshorne, Kirklees and Calderdale Improving Access to Psychological Therapies Clinical Manager, said: “We wanted to give our Single Point of Access teams and other local care providers a full picture of a patient’s interaction with the trust at the point of referral, to make sure they had visibility of patient demographics, previous appointments, contacts and progress notes.
 
“This not only reduces the risk of missing any relevant details on referral, it also means patients will no longer need to continually provide and repeat personal information at each care episode, therefore improving their experience”, added Hartshorne. 
 
The Viper360 Presentation Layer is a tool for care professionals that can be scaled to include patient interaction. It offers a broader many-to-many relationship to patient data allowing conditions for professionals to interact in real-time  

Viper360 will if adopted hughly benefit the West Midlands population enabling fast and accurate access to infomation and reducing the need for duplicate tests.
Current and planned activity: 
ReStart are currentley looking to invest time in the West Midlands on sharing the Viper360 stories and are looking towards the AHSN for support.
What is the intellectual property status of your innovation?:
ReStart are the holder of th IP
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
2
Read more
Hide details
Keli Shipley 30/01/2019 - 20:32 Archived Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
Many physical examinations require patients to undress. The Bare-Non Modesty Apron protects patients modesty. This single use, cost effective, dignity restoring garment reduces feelings of vulnerability & embarrassment for clinicians & patients.
Overview of Innovation:
NHS policies on Dignity & Respect state that patients have the absolute right to be treated with dignity & respect in a way that suits their needs & that patient modesty must be protected at all times by the provision of suitable garments & drapes.
 
The use of a Bare-Non® Modesty Apron in an examination allows the patient to feel more comfortable & empowered rather than experiencing what is usually considered an uncomfortable & awkward experience. This helps to create a more harmonious environment between the patient & the practitioner.
 
Single use disposable, hygienic & hypo-allergenic, the Bare-Non Modesty Apron has a front split & extensible neckline, meaning one size fits all. It is simply placed over the patient’s head prior to examination or treatment & covers the front torso to mid-thigh level.


 
Each Apron comes individually packed with a ‘Proof of Use’ sticker which can be signed & inserted into the patients notes or attached to other documentation such as an ECG tracing. Lightweight, comfortable & moisture resistant it allows quick unhindered access to the patients’ chest & abdomen should the need arise.
 
Over time, clinicians can become desensitised to patient’s in a state of undress, a condition Bare-Non identify as “Nudity Blindness”. This can leave patient’s feeling vulnerable & embarrassed & unable to participate fully in important aspects of their consultation such as shared decision making whilst they focus on their state of undress. Patients who have worn the Bare-Non Modesty Apron have reported feeling less inhibited, more empowered & more able to participate in their treatment or consultation without feeling the need to rush to put their clothes back on.
 
Current garment offerings have to be completely removed in a variety of settings, leaving the patient inadequately protected in terms of modesty & dignity. Sometimes clinicians are only provided with drapes, which have a tendency to fall off. Cases of compromised patient modesty can lead to patient distress & formal complaints, the impact of which can be personal, organisational & financial with devastating & long-lasting consequences for both patient & clinician.
 
The Bare-Non Modesty Apron is relevant for examination applications across multiple clinical areas. These include, but are not limited to; pre-op assessment clinics, outpatients, breast clinics, cardiac function suites, radiology & interventional radiology, cosmetic & reconstructive surgery & General Practice e.g. ECG testing.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Patient and medicines safety
Benefit to NHS:
Enabling a practitioner to perform a thorough examination front and back whilst protecting patient dignity at all times, whether female or male, young or old, is a very important criteria which is often overlooked.

The benefits of employing the Bare-Non Modesty Apron within the NHS are:
  1. Positively affects patient satisfaction and outcome measures, and shows a real commitment to understanding and acting upon Dignity and Respect concerns – compliance with relevant NICE and NHSE guidance etc.
  2. Supply chain efficiency improvements in terms of reducing laundered garment use.
  3. Financial in terms of cost savings over current garments and reduced claims for breach of dignity and respect.
In spite of the pressures the NHS comes under, Dignity and Respect in patient care is acknowledged as a critical component in caring for patients. Finding innovative, cost effective ways to further enhance the patient experience may have a favourable effect on outcomes related to Regulation 10. Patient satisfaction is an important aspect to the NHS as evidenced by the Patient Survey Programme which collates data into Overall Patient Experience Scores

The Bare-Non Modesty Apron, if measured against a standard textile or single use hospital examination gown is more cost effective. However, from research carried out by Bare-Non it is evident that standard textile examination gowns (36p per use) and single use disposable gowns (Medline Examination Gown 51p per use) are unsuitable garments for many of the examinations and procedures they are used for as they require removing in order for the clinician to perform examination or treatment. The drapes employed in some NHS departments are unfit for purpose as they do not stay in place and can lead to more claims of compromised patient modesty.

The Bare-Non Modesty Apron is presented as an individually wrapped item in a paper pouch. Its small footprint and handy box size means storage is easy in a variety of clinical settings. Being single use disposable has supply chain advantages over laundered products, as there is less movement and storage requirements are smaller.
Initial Review Rating
3.20 (2 ratings)
Benefit to WM population:
The Bare-Non® Modesty Apron has been designed to protect the modesty and dignity of patients when it is necessary for them to be undressed. This includes being examined, undergoing investigations or when having treatment.

Benefits are focused on the positive aspects of the innovation to the NHS nationally, with West Midlands based NHS units having early adopter advantages.

The Bare-Non® Modesty Apron enhances the patient experience, empowering the patient to be fully engaged even when in a state of relative undress. Its use provides a cost-effective solution, reducing the need for chaperone services and releasing staff back to direct patient care.

Many patients find undressing highly embarrassing and awkward. The Bare-Non® Modesty Apron provides a solution, leading to a more dignified and enhanced experience for all involved.

There is no need for a patient to remain topless during the majority of examinations. Using a Bare-Non® Modesty Apron ensures that the patient is adequately covered reducing the feeling of embarrassment and vulnerability, enabling the patient to feel more comfortable and empowered during the examination process.

Our aim is to make the Bare-Non® Modesty Apron widely available within all hospitals and clinics.

To view the product animation showing the new Bare-Non Modesty Apron click here

The use of a Bare-Non® Modesty Apron should be considered as a cost-effective device in helping to alleviate the need for chaperone services thereby releasing a valuable resource back to direct patient care.
Current and planned activity: 
As a single use, disposable item, the Bare-Non Modesty Apron enhances the patient experience, eliminates the requirement to launder products and storage requirements are smaller due to the slim, flat packaging.
 
We would like to engage with West Midlands healthcare providers to trial the use of the Bare-Non Modesty Apron as a cost effective alternative to gowns and drapes currently used.
 
In addition, as an SME based in the West Midlands Bare-Non has attendant incentives for job creation by establishing a local logistics hub with associated supply chain for national and international distribution.
What is the intellectual property status of your innovation?:
Patents pending in the UK & International.
Design protection in Europe via EUIPO.
Return on Investment (£ Value): 
N/A
Return on Investment (Timescale): 
N/A
Ease of scalability: 
Simple
Read more
Hide details
Trevor Norris 13/02/2019 - 10:56 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Innovative staff led Safety Board design supports safe and effective handover in care home
Overview of Innovation:
Handover of care in a  residential or nursing home is a complex, safety critical activity.   Inaccurate or incomplete handover can result in potential harm to a resident.  There is a vast amount of safety critical information conveyed in handover such as 
  • Repositioning frequency
  • Resuscitation status
  • Falls/ mobility status
  • Specialist Diet and hydration requirements
  • Time critical  / covert medication needs
  •  Advanced care planning needs
 this list goes on.
Furthermore the high use of temporary staff in the care sector means that it is likely that some staff will be unfamiliar with residents.  
Therefore ANY system which supports safe, effective handover has potential to reduce harm and  support good quality care.  It is well rescognised that the NHS and social care needs to build in safe system design to  support staff  and make it EASY for them to DO THE RIGHT THING-  to recognise that staff are HUMAN and therefore fallible.
 This innovative design of a safet board to support safe, effective  handover is a great example of safe system design. It captures key  information  about care needs  in a visual format using national symbols to denote risks. The board was designed and tested and refined by  the care home owner, manager and  front line staff and is an example of best pracice and collaborative working and  Quality Improvement methods.
 
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Long term conditions: a whole system, person-centred approach / Education, training and future workforce / Wealth creation / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
This innovation has potential  to benefit other care homes 
Initial Review Rating
1.80 (1 ratings)
Benefit to WM population:
 3x more residents in care homes than patient in the NHS and this is set to double in next 20 years
•Population aged 80ys and over projected to increase in West Midlands  in next 20 years from 33,874 (2016) to 45,441 (2035)
Care home sector   is in crisis in terms of funding, staff recruitment and retention - any system which support safe effective care in care homes is of value as the outlook for  futue provision of care homes is very uncertain
•Increasing frailty and dementia
Current and planned activity: 
the safety board is in use at t Rushall care home
A second board has been developed for use at a sister home iowned by Navigation care - the owner has expressed an interest  in offering this service to other care homes (  the safety baoards were  produced by  Company owned y Navigation care owner designs are wo Navigation 
What is the intellectual property status of your innovation?:
No IP issues - the safety board has been developed in collaboratiion with SPACE QI programme - evolved from staff ideas and examples of  safety boards from other care homes
Return on Investment (£ Value): 
low
Return on Investment (Timescale): 
3 years +
Ease of scalability: 
Simple
Rejection Reason:
Unsuitable Application
Read more
Hide details
Caroline Maries-Tillott 04/04/2019 - 19:08 Rejected Login or Register to post comments
0
0
Votes

Innovation 'Elevator Pitch':
As experts in digitising clinical pathways, we empower patients and clinicians through our virtual outpatient clinic platform. Our work at Barts demonstrated 3x reduction in DNAs and 10 additional patients seen per 4-hour clinic.
Overview of Innovation:

Ortus-iHealth has developed a downloadable app for your smartphone and tablet. Within the app, the patient and carers can do the following:
  • Video Consultations
  • Record symptoms and health statistics
  • Set reminders for taking medicines
  • Manage appointments
  • Set tasks to achieve health goals
  • View clinic letters in a centralised place
  • Receive specific health-related information, research and more
  • Patient satisfaction surveys


All this data is then available to the clinician for review through an accompanying web portal. PROMS and PREMS questionnaires with actionable data analytics are easily generated. Finally, the portal allows for a secure, excellent quality virtual consultations to take place, from anywhere and at any time.

Please use this link for a video of the patient experience and see the attached user manual for a sense of the clinician portal and workflow. Please also feel free to use the following dummy logins to try it for yourself:

Patient Login
Email test+wmahsn_patient@ortus-ihealth.com
Password 16May2003
Access WebiOSAndroid

Clinician Login
Email test+wmahsn_clinician@ortus-ihealth.com
Password 16May2003
Access Web
 
Support Staff Login
Email test+wmahsn_support@ortus-ihealth.com
Password 16May2003
Access Web
 
All data is held on a secure server in the UK Cloud. Our product is data protection compliant and up to date with the latest information governance standards as set out in the latest DSP toolkit.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Digital health / Innovation and adoption / Patient and medicines safety / Person centred care
Benefit to NHS:

Increased efficiency
  • 4x reduction of ‘did-not-attends’ from 10-12% to 3% - applied across the NHS this would save £750bn
  • 10 additional patients seen per week due to additional capacity
  • 0 adverse events
  • In a remote monitoring clinic, 8 patients can be ‘seen’ in 30 minutes rather than 3 hours
  • In a video clinic with pre-filled questionnaires, 8 patients can be seen in 70 minutes rather than 3 hours


Patient savings
  • 100% saved money
  • 97% saved >30 minutes


Patient satisfaction
  • 90% satisfied with the virtual clinic experience
  • 100% found appointment reminders useful
  • 83% valued access to clinical letters
Initial Review Rating
3.40 (2 ratings)
Benefit to WM population:
Please see above
Current and planned activity: 
We are already working with Barts Health to scale up across multiple departments catering to 3000 patient interactions including in Cardiology, Cardiothoracics, Respiratory, General Surgery and Oncology.
What is the intellectual property status of your innovation?:
Ortus owns the IP.
Return on Investment (£ Value): 
Very high
Return on Investment (Timescale): 
0-6 mon
Ease of scalability: 
Simple
Read more
Hide details
Dilraj Kalsi 29/04/2019 - 18:00 Publish Login or Register to post comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Sensium Wireless Vitals Monitoring is proven to lead to treatment of sepsis 6 hours quicker than NEWS, reduce LOS by 10% and readmission by 45%. The only wearable vital sign monitor with peer reviewed RCT data showing significant clinical benefits. 
Overview of Innovation:
In general care areas of a hospital vital signs are typically taken during routine observation rounds once every 4-8 hours. If a patient deteriorates between these observation rounds the warning signs can go undetected for hours, potentially leading to serious & costly consequences. 
 
Sensium is a discreet, wearable, wireless system for monitoring vital signs of patients outside of high acuity areas. A light comfortable sensor worn on the patient’s chest accurately and reliably monitors and reports vital signs, providing data every 2 minutes. By notifying clinicians of changes in patients’ vital signs Sensium brings the nurse to the deteriorating patient, allowing intervention before the condition worsens, thereby improving patient outcomes, shortening hospital stays and lowering treatment costs. It enables nurses to prioritise patient care where it is needed most.   Sensium is focussed exclusively on general care clinicians whose patients currently do not have the safety and security of continuous vital sign monitoring.
 
The Sensium Patch provides accurate and continuous monitoring of the 3 key leading indicators of patient deterioration: heart rate (HR), respiration rate (RR) & axillary temperature (T). Sensium wirelessly communicates this physiological data via safe and secure low power wireless communication to the Sensium bridges placed through the ward area.  Sensium allows patients to ambulate freely, untethered to static and expensive equipment whilst still having the reassurance of continuous monitoring.
 
The bridges are connected into the hospital IT system, and software installed on the hospital network allows patient data to be seamlessly conveyed. Crucially, notifications can be configured to work with hospital pager systems/mobile notification devices, giving the clinical team data when they need it, where they need it. To save time and ensure accuracy Sensium can be easily integrated with the hospital admission, discharge, transfer systems and electronic medical records.
Stage of Development:
Market ready and adopted - Fully proven, commercially deployable, market ready and already adopted in some areas (in a different region or sector)
WMAHSN priorities and themes addressed: 
Digital health / Innovation and adoption / Patient and medicines safety
Benefit to NHS:
Currently approximately 10% of patients are harmed during their hospital stay and this represents a cost to the NHS of over £2.5bn just to cover the additional length of stay for these patients. Improved monitoring regimes and early detection of deterioration is key to reducing this significant burden.
 
Patients undergoing major abdominal surgery have an 30-40% risk of complications with a leading complication being sepsis. Hospital acquired (HA) sepsis (e.g. sepsis that develops after a surgical procedure) has twice the mortality rate and twice the treatment cost of community-acquired sepsis and rates of HA sepsis are rising. A recently-published study aimed to assess differences in outcomes between patients being monitored using the Sensium system in addition to intermittent (routine) observations and patients being monitored by routine observations alone [1].  The study was designed as a pilot cluster-randomised, prospective, parallel-group, controlled single-centre pilot study and consenting participants were allocated to one of two monitoring arms for the length of their admission. The primary outcome measure was time to antibiotics after the first evidence of sepsis, defined according to a revised consensus conference definition in 2001 [2]. Secondary outcome measures included length of hospital stay, 30-day readmission rate, mortality and patient acceptability. 226 patients were randomised between January and June 2017. 140 patients were randomised to continuous remote monitoring; 86 patients were randomised to receive intermittent monitoring alone. There were a similar number of complications and sepsis events across both arms of the study, indicating that both groups had similar baseline risk factors.

On average, patients receiving Sensium continuous monitoring were administered antibiotics 6.4 hours sooner after evidence of sepsis, had a 10% shorter average length of hospital stay and were 45% less likely to require readmission within 30 days of discharge than those patients in the intermittent monitoring group. Patients found the monitoring device to be acceptable in terms of comfort and perceived an enhanced sense of safety. Given that every hour’s delay in treatment of sepsis has been shown to be associated with a 7% increase in risk of mortality [3], a 6-hour reduction in time to administer antibiotics is a significant result and further studies are ongoing to demonstrate similar benefits in other clinical settings.
Initial Review Rating
5.00 (1 ratings)
Benefit to WM population:
Sensium’s solution offers several key benefits to the West Midlands and its population. The key benefits of Sensium compared to competitor products are as follows:

Product Performance: Sensium uses clinically accepted ‘gold standard’ methods of vital sign measurement, deriving heart rate from single-lead ECG, respiration rate from thoracic impedance, and temperature from an axilla sensor.  In contrast, our competitors derive respiratory rate from pulse or ECG measurements which has known limitations in certain clinical conditions and provide only skin temperature measurement which has limited clinical value.

Customer Focus: Sensium is recognised by our customers for exceptional customer support.  Once we deploy our product at a clinical site, we provide on-site technical support for installation and troubleshooting and clinical support for training for as long as it takes for the system to be truly embedded in the clinical workflow and providing tangible benefits. Sensium has clinical and technical staff based in the West Midlands region on hand for support.

Clinical Evidence: Sensium understand that medicine is an evidence-based science and we are engaged in a series of clinical research studies designed to show clinical efficacy, improved clinical outcomes, and health economic benefits.  To date, Sensium are the only company providing wearable wireless technology for early detection of patient deterioration that have independent and peer-reviewed publications showing benefits of our technology demonstrated through randomised controlled trials
 
 
Current and planned activity: 
Our initial engagement with the NHS has been to introduce Sensium to general surgery wards and areas with high risk and infection prone patients e.g. colorectal, trauma and haematology wards. Discussions with many NHS hospitals have also shown significant interest and benefit for the use of Sensium for ‘Step down’ areas for patients who aren’t sick enough for ITU but still show cause for concern and for high risk conditions such as Hospital Acquired Sepsis opioid depression and AF. 

We have engaged with the Emergency Laparotomy Collaborative with a view to patch these types of patients. When approaching the NHS, we have been primarily engaging with Anaesthetists as they witness many patient deteriorations, as well as consultants and sepsis/patient deterioration leads, matrons and clinical IT leads. We plan to interact more directly with medical directors and members of the directorate earlier on in the process if possible. Future plans include home monitoring to follow patients’ home.
What is the intellectual property status of your innovation?:
CE mark and FDA 510(k) cleared.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
N/A
Ease of scalability: 
2
Co-Authors:
Read more
Hide details
Sonia Hussein 18/05/2019 - 11:34 Publish 4 comments
0
0
Votes
-99999
Innovation 'Elevator Pitch':
Knowing Me!
 
Is a free online booklet to enable people to better identify and react to the three D’s – Dementia, Depression and Delirium which are all closely linked.
Overview of Innovation:
What did you wish you knew about dementia at the point of diagnosis that you now know?

This is what we asked people with dementia, their carers and the professionals that work with them.

We took what people told us they wished they knew, broke it into bite-size easy to read pieces and created our free learning resource: Knowing Me!


Knowing Me! Is a free online booklet to enable people to better identify and react to the three D’s – Dementia, Depression and Delirium which are all closely linked. https://www.lifestorynetwork.org.uk/pages/15-knowing-me  This booklet was co-created by people with dementia and their carers with consideration to what they wish they knew from day one of diagnosis. 
 
This free online learning has been downloaded by people with dementia, carers and professionals that want to have a useful resource to dip into.

Because of its popularity and feedback we have developed a blended learning approach which includes face to face training, online training and printed resources.

This approach to training is becoming popular with health care teams in Northern England who want to be more than just 'dementia friends' but seek to understand the disability and better support those they work with.
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Long term conditions: a whole system, person-centred approach / Patient and medicines safety / Person centred care
Benefit to NHS:
Staff quickly identify the differences between, dementia, depression and delirium and can react appropriately ensuring the person gets the right care at the right time.
Initial Review Rating
3.00 (1 ratings)
Benefit to WM population:
Many health care staff still don't feel confident in dealing with dementia and the issues surrounding it such as memory loss, end of life planning, wellbeing issues and dealing with delerium.

Many staff are having increasing interations with those affected by dementia and want more depth of understanding than being just 'dementia friends'.

This blended learning approach, co-produced by people with dementia enables staff to dig deeper into dementia, not only being better able to spot the symptoms and challenges but being empowered to know how to react to them.

Many people with dementia and their carers live in misery as the depression or delirium is an assumed part of dementia that cannot be treated.  We know this can be treated and this resource enables staff to identify and react to the issues that face a person with dementia.

This blended learning can easily be rolled out across the West Midlands for staff at all levels who have interactions with those effected by dementia.  The training is fun, fast paced and applicable to their role.  They will be able to take away key learnings to implement in their practice improving outcomes for patients and improving satisfaction levels for all involved.

The staff that have recieved this training have said it has empowered them and given them renewed confidence when supporting people with dementia.
 
Current and planned activity: 
We look to disseminate this free online resource to ensure its uptake by NHS staff at all levels.  This booklet was co-produced by people with dementia and their carers and enables staff to have a strong understanding around dementia, depression and delirium.
 
Along with this we look to roll out face to face training to accompany this resource
What is the intellectual property status of your innovation?:
This is held by Life Story Network
Return on Investment (£ Value): 
medium
Return on Investment (Timescale): 
6-12 mon
Ease of scalability: 
Simple
Read more
Hide details
Thomas Hughes 18/06/2019 - 14:07 Publish 1 comment
0
0
Votes
-99999
Innovation 'Elevator Pitch':
The NHS is on a digital transformation journey. Our online digital education service provides everyone across the NHS with an introduction to the digital 'fundamentals' to enable everyone to engage in this journey. 
Overview of Innovation:
DEfactoEd is an online digital education company founded in 2017 by former Big4 Consulting Partners, Commercial leaders and Digital academics to provide people with a highly engaging and structured introduction to digital. 

Digital technologies are advancing at a rate far faster than the capabilities of people to adapt; in many organisations this is impeding the pace at which the benefits and risks of the new technologies can be delivered. Our online programmes address this critical capability gap.

Our programmes have been succesfully deployed into major corporates and other institutions and are now being made available for the NHS workforce. We intend to offer 3 core online programmes :

1. Digital Leadership (for Clinical and NonClinical leaders) addressing:
  • Digital disruption (what's happening, where are things going?)
  • Digital opportunities and risks
  • Core digital technologies and NHS application
  • Leadership in a digital organisation
  • Transforming to digital
  • Ethics - impact of AI
  • Data - practical insights
  • Cyber - the Human Firewall
2. Digital Essentials (for NHS Digital Champions addressing a subset of the modules above)
3. Digital Awareness (for all other NHS Staff to provide the wider workforce with an abbreviated introduction to the concepts of digital).

Our programmes have been designed to appeal to modern learning styles; they are modular, multi-media (include videos, games etc, ebooks, etc) and available on all devices, 24/7. People will be able to fit this learning around their personal schedules rather than take time out from their busy daily routines.

Our release plan is as follows:
  1. Pilot phase (Q3 2019)  - pilots are in progress with UK Trust hospitals. Pilot involves inviting c50 Leaders and Staff from selected CSU's/Support Functions to engage in an 'Innovation Sprint' to complete the course and apply the learning to develop 'Ideas' on digital adoption in the Pilot sites. This will deliver immediate operational benefits and shift the teams toward 'digital culture'.
  2. Build phase (Q4 2019) - to modify programmes and make programmes fully relevant to NHS audiences
  3. Promotion and Launch (Q4 2019).
 
 
Stage of Development:
Close to market - Prototype near completion and final form may require additional validation/evaluation and all CE marking and regulatory requirements are in place
WMAHSN priorities and themes addressed: 
Mental Health: recovery, crisis and prevention / Advanced diagnostics, genomics and precision medicine / Education, training and future workforce / Wealth creation / Digital health / Patient and medicines safety / Person centred care
Benefit to NHS:
Our programmes will deliver:
  1. ​Rapid upskilling and awareness of 'digital' across large scale NHS audiences :
    • Enabling people to adapt and be relevant in their roles as digital becomes more prevalent (without adaption, people will become sidelined and at risk in their roles as technology takes over)
    • Giving people the confidence to engage in digital
      • get them curious about digital and want to learn more
      • engage in digital dialogue and innovate
      • encourage idea creation from all areas of the NHS
    • Giving leaders the insights to make improved decisions on:
      • digital development priorities
      • risk management (ethics, cyber etc)
      • governance to deliver the most effective returns from digital investments
      • how they need to work together as leaders rather in silos to improve the overall patient experience
  2. Contribute to shifting the culture of the NHS to digital (at Leadership levels and across the wider organisation)
    • Get people to deploy digital to improve the 'patient experience' from point of entry to exit through the care system
    • Get people to recognise the potential for deploying digital to drive operational improvements
  3. Rapid acceleration of idea creation and deployment into individual departments and across the wider organisation.
    1. Make education an engaging and highly relevant experience for everyone
    2. Link education directly into innovation by deploying the programmes in 'Innovation Sprint's' to create momentum.
Initial Review Rating
3.80 (1 ratings)
Benefit to WM population:
The benefits to the WM population will be as for the wider NHS England population, above. Our programmes are designed for a national audience.
Current and planned activity: 
Referred to above.

We are currently engaging with NHS Trusts to 'Pilot' our programmes and intend to progress to Build and Lauch later in Q4 2019.
What is the intellectual property status of your innovation?:
IP is owned by DEfacto Learning Solutions Limited.
Return on Investment (£ Value): 
high
Return on Investment (Timescale): 
1 year
Ease of scalability: 
Simple
Read more
Hide details
david knight 01/07/2019 - 11:29 Publish Login or Register to post comments
0
0
Votes
-99999